
    
      A Phase 1 Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of
      CNF2024 as a Single-Agent Treatment in Subjects with HER2- Advanced Breast Cancer or in
      Combination with Trastuzumab in Subjects with HER2+ Advanced Breast Cancer
    
  